Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples-Reference-Cited by-同舟云学术

Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples

Published:2017-11 Issue:6 Volume:18 Page:e473-e479
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Cho Jong Ho,Sorensen Steffen Filskov,Choi Yoon-La,Feng Yu,Kim Tae-Eun,Choi Heyjoo,Georgsen Jeanette Baehr,Dolled-Filhart Marisa,Emancipator Kenneth,Meldgaard Peter,Sun Jong-Mu,Kim Hong Kwan,Choi Yong Soo,Shim Young Mog,Zhou Wei,Hager Henrik,Kim Jhingook

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non–small-cell lung cancer;Azuma;Ann Oncol,2014

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

5. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study;Oncology Letters;2024-06-03

2. Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis;Frontiers in Oncology;2024-01-31

3. Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology;Cancer Reports;2023-02-22

4. What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?;Thoracic Cancer;2022-08-29

5. Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma;Frontiers in Oncology;2022-08-22